Seegene presents a new roadmap for standardization of molecular diagnostics and brings a healthier, better future
Seegene’s MDx technology leads to effective treatment
Seegene is recreating new values through various business opportunities and partnerships with numerous global companies through its superior technologies. Expansion and growth of molecular diagnostics market generates and contributes Seegene’s consistent growth over the years.
MDx has become an outstanding diagnostic method that introduced a new paradigm
Molecular diagnostics (MDx) is the latest in vitro diagnostics that detects causes of disease by analyzing nucleic acids such as DNA and RNA which contain genetic information. Powered by high accuracy and rapid result delivery, this diagnostics is suitable for early diagnosis and holds a strong potential for personalized care.
With high sensitivity and accuracy, molecular diagnostics is used to detect infectious/genetic diseases, and in recent years, it has been widely used to detect MERS, H1N1, and avian influenza infections.